Biocon Limited — Updates, 28-02-2025: Press Release

Biocon Limited has launched its Glucagon-like peptide-1 (GLP-1) peptide, Liraglutide, in the United Kingdom. This drug-device combination will be sold under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management. This launch positions Biocon as the first generics company to receive approval for gLiraglutide in a major regulated market, showcasing its strong manufacturing and scientific capabilities.

The introduction of gLiraglutide addresses a significant gap in affordable treatment options for diabetes and obesity, aligning with the company's commitment to enhancing healthcare access. The CEO highlighted that this launch is a strategic milestone, with plans for further expansion of gLiraglutide into European markets, the U.S., and other regions. Given the promising growth potential of GLP-1 therapies, investors should monitor Biocon’s progress in this field as it strengthens its market presence.